, , pp.25-26
,
, , pp.27-28
Présentation clinique, évolution naturelle et démarche diagnostique des gliomes, vol.28, p.30 ,
,
31-34 2.2.1.1 Vitesse ou pente de croissance tumorale, pp.33-34 ,
,
, , pp.36-42
, 3.1.4 TEP aux analogues nucléosidiques : 18 F-FLT, pp.36-39
40 3.2.2 Préparation des patients, modalités d'acquisition ,
,
,
, Discussion des résultats et comparaison avec la littérature, pp.56-57
, , pp.57-58
,
, , pp.60-64
,
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010, Neuro-Oncol, vol.15, issue.2, pp.1-56, 2013. ,
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer, vol.113, pp.1953-68, 2008. ,
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system, J Natl Cancer Inst, vol.103, issue.9, pp.714-750, 2011. ,
MRIsuspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging. juin, vol.39, issue.6, pp.1021-1030, 2012. ,
The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol (Berl). août, vol.114, issue.2, pp.97-109, 2007. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl). juin, vol.131, issue.6, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Natural history of incidental World Health Organization grade II gliomas, Ann Neurol, vol.68, issue.5, pp.727-760, 2010. ,
Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas, Ann Neurol. sept, vol.60, issue.3, pp.380-383, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00163977
Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas, Neuro-Oncol. mai, vol.15, issue.5, pp.595-606, 2013. ,
Continuous growth of mean tumor diameter in a subset of grade II gliomas, Ann Neurol. avr, vol.53, issue.4, pp.524-532, 2003. ,
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse lowgrade gliomas, Neuro-Oncol. août, vol.16, issue.8, pp.1100-1109, 2014. ,
,
, J Radiol. juin, vol.87, issue.6, pp.822-854, 2006.
Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study, Int J Radiat Oncol Biol Phys. 1 mars, vol.70, issue.3, pp.773-81, 2008. ,
Genetic alterations and signaling pathways in the evolution of gliomas, Cancer Sci. déc, vol.100, issue.12, pp.2235-2276, 2009. ,
Molecular classification of low-grade diffuse gliomas, Am J Pathol. déc, vol.177, issue.6, pp.2708-2722, 2010. ,
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis, Acta Neuropathol (Berl). déc, vol.120, issue.6, pp.719-748, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01848106
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.16, issue.5, pp.1597-604, 2010. ,
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, vol.75, issue.17, pp.1560-1566, 2010. ,
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol Off J Am Soc Clin Oncol. 1 sept, vol.27, issue.25, pp.4150-4154, 2009. ,
Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysis-a comparative study in human gliomas, Clin Neuropathol. déc, vol.27, issue.6, pp.378-87, 2008. ,
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, J Clin Oncol Off J Am Soc Clin Oncol. 20 juin, vol.9402, issue.18, pp.2707-2721, 2006. ,
DOI : 10.1200/jco.2005.04.3414
URL : http://www.brainlife.org/reprint/2006/cairncross_g060620.pdf
Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas, Clin Cancer Res Off J Am Assoc Cancer Res. mai, vol.8, issue.5, pp.1117-1141, 2002. ,
Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis, Oncol Res, vol.12, issue.2, pp.107-119, 2000. ,
Clinical applications of PET in brain tumors, J Nucl Med Off Publ Soc Nucl Med. sept, vol.48, issue.9, pp.1468-81, 2007. ,
Pitfalls in the diagnosis of brain tumours, Lancet Neurol. nov, vol.5, issue.11, pp.937-985, 2006. ,
Brain Tumors: An Update on Clinical PET Research in Gliomas, Semin Nucl Med. janv, vol.47, issue.1, pp.5-17, 2017. ,
DOI : 10.1053/j.semnuclmed.2016.09.004
11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas, Mol Imaging Biol MIB Off Publ Acad Mol Imaging. févr, vol.10, issue.1, pp.1-18, 2008. ,
Imaging 18 Ffluorodeoxy glucose/ 11 C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema, J Neurooncol. janv, vol.106, issue.2, pp.417-442, 2012. ,
3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro, J Nucl Med Off Publ Soc Nucl Med. déc, vol.45, issue.12, pp.2116-2138, 2004. ,
18F-FDOPA kinetics in brain tumors, J Nucl Med Off Publ Soc Nucl Med, vol.48, issue.10, pp.1651-61, 2007. ,
DOI : 10.2967/jnumed.106.039321
URL : http://jnm.snmjournals.org/content/48/10/1651.full.pdf
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine, Eur J Nucl Med Mol Imaging. nov, vol.30, issue.11, pp.1561-1568, 2003. ,
DOI : 10.1007/s00259-003-1259-1
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med Off Publ Soc Nucl Med, vol.51, issue.10, pp.1532-1540, 2010. ,
DOI : 10.2967/jnumed.110.078592
URL : http://jnm.snmjournals.org/content/51/10/1532.full.pdf
Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice, Clin Nucl Med. sept, vol.40, issue.9, pp.429-435, 2015. ,
Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.20, issue.13, pp.3550-3559, 2014. ,
DOI : 10.1158/1078-0432.ccr-13-1440
URL : http://clincancerres.aacrjournals.org/content/20/13/3550.full.pdf
IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas, Eur J Nucl Med Mol Imaging. 14 mars, 2017. ,
DOI : 10.1007/s00259-017-3668-6
URL : https://hal.archives-ouvertes.fr/hal-01735109
Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion-and perfusion-weighted imaging, Eur Radiol. févr, vol.27, issue.2, pp.578-88, 2017. ,
DOI : 10.1007/s00330-016-4328-0
Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma, J Nucl Med Off Publ Soc Nucl Med. avr, vol.48, issue.4, pp.519-546, 2007. ,
DOI : 10.2967/jnumed.106.037895
URL : http://jnm.snmjournals.org/content/48/4/519.full.pdf
Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy, J Neurosurg. févr, vol.102, issue.2, pp.318-345, 2005. ,
DOI : 10.3171/jns.2005.102.2.0318
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas, Neuro-oncology. mai, vol.18, issue.5, pp.744-51, 2016. ,
DOI : 10.1093/neuonc/nov282
URL : https://academic.oup.com/neuro-oncology/article-pdf/18/5/744/6881318/nov282.pdf
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies, J Nucl Med Off Publ Soc Nucl Med. mars, vol.47, issue.3, pp.410-418, 2006. ,
Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas, Nucl Med Commun. juin, vol.33, issue.6, pp.621-626, 2012. ,
DOI : 10.1097/mnm.0b013e3283529984
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, Lancet Oncol. sept, vol.15, issue.10, pp.1100-1108, 2014. ,
DOI : 10.1016/s1470-2045(14)70379-1
URL : https://www.zora.uzh.ch/id/eprint/100322/1/Stupp.pdf
New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach, Neuro-Oncol. mars, vol.17, issue.3, pp.332-374, 2015. ,
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma, Neuro-Oncol. févr, vol.18, issue.2, pp.283-90, 2016. ,
Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET, Br J Radiol, vol.89, p.20160476, 1066. ,
FDOPA PET-CT of Nonenhancing Brain Tumors, Clin Nucl Med. avr, vol.42, issue.4, pp.250-257, 2017. ,
DOI : 10.1097/rlu.0000000000001540
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma, Eur J Nucl Med Mol Imaging. 21 janv, 2017. ,
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients, J Nucl Med Off Publ Soc Nucl Med, vol.55, issue.10, pp.1611-1617, 2014. ,
18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience, Eur J Radiol. août, vol.71, issue.2, pp.242-250, 2009. ,
DOI : 10.1016/j.ejrad.2008.04.018
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients, J Nucl Med, vol.55, issue.10, pp.1611-1617, 2014. ,
Intraindividual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors, Neuro-oncology. mars, vol.16, issue.3, pp.434-474, 2014. ,